Liquid Biopsy Market is anticipated to grow at a CAGR of 17% during 2021-2027

Liquid Biopsy Market is anticipated to grow at a CAGR of 17% during 2021-2027
Trends and Forecast for the Global Liquid Biopsy Market
Trends, opportunities, and forecast for the liquid biopsy market to 2027 by product (assay kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers), application (oncology and non-cancer liquid biopsies), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), end use and region

The global liquid biopsy market is projected to reach $10.4 billion by 2027, at a CAGR of 17% during 2021-2027. The growth of liquid biopsy market is driven by increasing prevalence of cancer, preference for non-invasive procedures, and increasing need of early detection of high precision diseases in real time.

Some of the Key Questions answered in this exclusive report are:

Q.1 What are some of the most promising, high-growth opportunities for the liquid biopsy market by product (assay kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers), application (oncology and non-cancer liquid biopsies), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end uses), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2 Which segments will grow at a faster pace and why?

Q.3 What are the business risks and threats to the liquid biopsy market?

Q.4 What are some changing demands of customers in the liquid biopsy market?

Q.5 What are the new developments in the liquid biopsy market? Which companies are leading these developments?

Q.6 What strategic initiatives are being implemented by key players for business growth?

Q.7 What are some of the competitive products and processes in this liquid biopsy area and how big of a threat do they pose for loss of market share via product substitution?

Q.8 What M&A activity has occurred in the last 5 years in this liquid biopsy market?

Emerging trends, which have a direct impact on the dynamics of the industry, include usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector.

Market Segmentation:

Based on circulating biomarker, the liquid biopsymarket is segmented into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers. Lucintel forecasts that the circulating tumor DNA (ctDNA) market accounted for the largest share of the market in 2020 and is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in early stage.     

Asia Pacific is expected to largest region and is also expected to witness the highest growth over the forecast period due to rising non-invasive treatment, a rising incidence of cancer, and improving healthcare infrastructure.

Key Players in the liquid biopsy market are Guardant, Bio-Rad Laboratories, Qaigen, MDxHealth, Myriad Genetics, Biocept, Roche, Illumina, and Thermofisher.

Request Sample Pages by clicking on

https://www.lucintel.com/liquid-biopsy-market.aspx

The report helps stakeholders understand the pulse of the market and provides them with information on key drivers, restraints, challenges, and opportunities for market growth. It would also help to understand the competitors better and gain more insights to improve their position in the business.

About Lucintel

Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.

Media Contact
Company Name: Lucintel
Contact Person: Brandon Fitzgerald
Email: Send Email
Phone: 303.775.0751
Address:8951 Cypress Waters Blvd., Suite 160
City: Dallas
State: TEXAS
Country: United States
Website: https://www.lucintel.com/


Posted

in

by

Tags: